MedPath

Neurimmune AG

🇨🇭Switzerland
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy

Phase 1
Completed
Conditions
Amyloid Transthyretin Cardiomyopathy
Interventions
Drug: Placebo
First Posted Date
2020-04-24
Last Posted Date
2023-11-03
Lead Sponsor
Neurimmune AG
Target Recruit Count
46
Registration Number
NCT04360434
Locations
🇫🇷

Hôpital Henri Mondor, Créteil, France

🇫🇷

CHU de Rennes - Hôpital Pontchaillou, Rennes, France

🇫🇷

CHU Toulouse - Hôpital Rangueil, Toulouse, France

and more 3 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.